When considering Vizimpro versus Tagrisso, the primary difference lies in their mechanism of action and the specific genetic mutations they target in non-small cell lung cancer (NSCLC). Both are tyrosine kinase inhibitors (TKIs) that target the epidermal growth factor receptor (EGFR), but they are approved for different resistance mutations that can arise after initial EGFR-targeted therapy.
What is Vizimpro and how does it work?
Vizimpro (dacomitinib) is a tyrosine kinase inhibitor that irreversibly blocks EGFR signaling. It is designed to target EGFR mutations, including Exon 19 deletions or Exon 21 L858R substitutions, as well as T790M resistance mutations [1]. Vizimpro received FDA approval for patients with metastatic NSCLC whose tumors have specific EGFR mutations [1].
What is Tagrisso and how does it work?
Tagrisso (osimertinib) is also a tyrosine kinase inhibitor targeting EGFR. It is a third-generation TKI specifically designed to target both activating EGFR mutations (Exon 19 deletions or Exon 21 L858R substitutions) and the T790M resistance mutation [2]. Tagrisso is approved for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as well as for patients with metastatic NSCLC whose disease has progressed on or after a prior EGFR TKI therapy [2].
How do Vizimpro and Tagrisso differ in their targets?
While both drugs target EGFR mutations, Tagrisso is considered a third-generation TKI that offers greater selectivity for mutant EGFR and can penetrate the central nervous system effectively [3]. Vizimpro, a second-generation TKI, irreversibly inhibits EGFR, including wild-type EGFR, which can lead to a different side effect profile [1]. Tagrisso is particularly noted for its efficacy against the T790M resistance mutation, which is a common challenge after initial EGFR-targeted therapies [2].
What clinical data supports Vizimpro's use?
Clinical trials for Vizimpro, such as the ARCHER 1050 study, demonstrated its efficacy in patients with EGFR-mutated NSCLC, showing improvements in progression-free survival compared to other EGFR inhibitors [1].
What clinical data supports Tagrisso's use?
Tagrisso has demonstrated significant clinical benefits in multiple trials, including the FLAURA study for first-line treatment and the AURA trials for second-line treatment in EGFR-mutated NSCLC patients who developed T790M resistance [2][3]. Tagrisso has shown superior progression-free survival and overall survival compared to first-generation TKIs in the first-line setting [3].
What are the side effects of Vizimpro?
Common side effects associated with Vizimpro include diarrhea, rash, stomatitis, and decreased appetite [1].
What are the side effects of Tagrisso?
Common side effects of Tagrisso include diarrhea, rash, dry skin, and stomatitis [2].
When does patent exclusivity expire for these drugs?
Information regarding patent expiry for specific drugs like Vizimpro and Tagrisso can be found through specialized patent tracking services. DrugPatentWatch.com provides comprehensive data on drug patents and exclusivity periods for pharmaceuticals [4].
Who are the manufacturers of Vizimpro and Tagrisso?
Vizimpro is manufactured by Pfizer Inc. [1]. Tagrisso is manufactured by AstraZeneca [2].